ArticlePloS one2016

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.

Xue Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.